To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

VANCOUVER, British Columbia, November 07, 2024 -- ( BUSINESS WIRE )-- AbCellera (Nasdaq: ABCL) today announced new data on ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted ...

Liver failure encompasses a range of severe clinical syndromes resulting from the deterioration of liver function, triggered ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS ... Safety concerns include low levels of grade ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed ...

"SOT201 demonstrates a superior ability to reinvigorate exhausted tumoral CD8 + T cells with a high cytotoxicity and minimal cellular exhaustion compared to the related cytokine PD1-IL2v. These data ...

Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by acute deterioration of liver function ...